Novo Nordisk AS (NVO) reports strong sales and profit growth, while addressing compounding challenges and expanding its ...

A new generation of GLP-1 drugs promising fast results continues to rock the weight loss industry, which has emphasized ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Novo Nordisk stock rose after the Danish pharma giant posted better-than-expected quarterly earnings, but cuts its guidance ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.